Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-05 10:55 am Sale |
2024-04-05 | 13D | NGM Biopharmaceuticals, Inc. NGM |
COLUMN GROUP L P | 1,000 100.000% |
-22,078,509 (-100.00%) |
Filing History |
| 2024-02-26 5:16 pm Unchanged |
2024-02-25 | 13D | NGM Biopharmaceuticals, Inc. NGM |
COLUMN GROUP L P | 22,079,509 26.700% |
0 (Unchanged) |
Filing History |
| 2024-02-14 6:12 pm Sale |
2023-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM |
EcoR1 Capital LLC | 2,385,873 2.900% |
-4,049,645 (-62.93%) |
Filing History |
| 2024-02-13 5:09 pm Sale |
2023-12-29 | 13G | NGM Biopharmaceuticals, Inc. NGM |
The Vanguard Group | 2,770,574 3.350% |
-1,718,575 (-38.28%) |
Filing History |
| 2023-12-29 4:05 pm Purchase |
2023-12-28 | 13D | NGM Biopharmaceuticals, Inc. NGM |
COLUMN GROUP L P | 22,079,509 26.700% |
1,094,533 (+5.22%) |
Filing History |
| 2023-10-06 2:34 pm Sale |
2023-09-30 | 13G | NGM Biopharmaceuticals, Inc. NGM |
BLACKROCK INC BLK |
3,839,879 4.600% |
-318,764 (-7.67%) |
Filing History |
| 2023-02-13 12:57 pm Sale |
2022-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM |
Rho Ventures V L.P. | 430,783 0.500% |
-3,372,487 (-88.67%) |
Filing History |
| 2023-02-09 11:27 am Purchase |
2022-12-30 | 13G | NGM Biopharmaceuticals, Inc. NGM |
The Vanguard Group | 4,489,149 5.490% |
4,489,149 (New Position) |
Filing History |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM |
BLACKROCK INC BLK |
4,158,643 5.100% |
4,158,643 (New Position) |
Filing History |
| 2022-10-28 5:34 pm Purchase |
2022-10-18 | 13G | NGM Biopharmaceuticals, Inc. NGM |
EcoR1 Capital LLC | 6,435,518 8.000% |
6,435,518 (New Position) |
Filing History |
| 2022-06-10 4:14 pm Purchase |
2022-06-01 | 13D | NGM Biopharmaceuticals, Inc. NGM |
COLUMN GROUP L P | 20,984,976 26.500% |
1,951,343 (+10.25%) |
Filing History |
| 2022-02-03 5:23 pm Purchase |
2022-01-24 | 13D | NGM Biopharmaceuticals, Inc. NGM |
COLUMN GROUP L P | 19,033,633 24.500% |
1,378,422 (+7.81%) |
Filing History |
| 2021-02-16 2:53 pm Purchase |
2020-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM |
Rho Ventures V L.P. | 3,803,270 5.500% |
12,604 (+0.33%) |
Filing History |
| 2021-02-12 5:25 pm Purchase |
2020-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM |
Rho Ventures V L.P. | 3,790,666 5.500% |
6,000 (+0.16%) |
Filing History |
| 2020-11-20 4:36 pm Sale |
2020-11-20 | 13G | NGM Biopharmaceuticals, Inc. NGM |
Topspin Fund L.P. | 3,320,498 4.800% |
-1,512,836 (-31.30%) |
Filing History |